This report examines Europe’s clinical research labour market as it stabilises following a turbulent 2024, with overall hiring projected to rise modestly by 0.4%. It explores how CROs and biotech firms are driving recovery, supported by regulatory clarity and renewed investor confidence, while pharmaceutical companies adopt a more selective, efficiency-focused hiring approach.
According to the latest Life Sciences Labour Market Trends report by CPL and market data analysts Vacancysoft, key recruitment trends show that in 2022, there were over 4,100 new scientific vacancies published in the ‘Golden Triangle’ (Cambridge, London and Oxford). This translates to a slight decrease from 2021, when there were over 4,500 jobs, resulting in a year-on-year fall of 9.1%.
Perhaps inevitably, the post-pandemic period has resulted in a hangover for the sector, as the combination of quantitative tightening leading to a slowdown in funding for emerging biotechnology firms, combined with the delays associated with getting new trials approved over the period, has meant that in recruitment terms, 2023 really was a slow year. Indeed, vacancies in 2023 were 42.6% lower than in 2022.
While 2023 has seen significantly lower levels of recruitment for clinical-specific functions, the forecast for 2024 is bullish, with the immediate projection being for two times more clinical vacancies in 2024 than in 2023.
